FDA Modernization Act 3.0

The FDA Modernization Act 3.0 requires the FDA to issue a final rule within 180 days of enactment to implement regulations for nonclinical testing methods used in drug development. This affects pharmaceutical companies developing new drugs by establishing standardized requirements for preclinical safety testing before human trials. The bill also makes a technical amendment to renumber a subsection related to clinical trial diversity plans, clarifying existing provisions without changing their substance. The key change is the FDA's obligation to finalize these testing regulations, aiming to modernize the drug approval process.